BioTuesdays

Category - Markets

Maxim starts Quoin Pharma at buy; PT $5

Maxim Group initiated coverage of Quoin Pharmaceuticals (NASDAQ:QNRX) with a “buy” rating and price target of $5. The stock closed at $1.74 on Jan.6. Quoin is a clinical-stage company developing therapies for rare...

Nkarta Therapeutics

WB starts Nkarta at OP; fair-value estimate $35

William Blair launched coverage of Nkarta (NASDAQ:NKTX) with an “outperform” rating and fair-value estimate of $35. The stock closed at $14.27 on Jan. 5. Nkarta is developing allogeneic chimeric antigen receptor (CAR)...

Cardiff Oncology

WB starts Cardiff Oncology at outperform

William Blair initiated coverage of Cardiff Oncology (NASDAQ:CRDF) with an “outperform” rating. The stock closed at $6.43 on Jan.4. Cardiff is advancing on vansertib, a specific PLK1 inhibitor, which “we view as a...

P3 Health Partners

WB starts P3 Health Partners at outperform

William Blair launched coverage of P3 Health Partners (NASDAQ:PIII) with an “outperform” rating, projecting 2022 revenue of 815.1-million; 2023 revenue of $1.2-billion; and 2024 revenue of $1.7-billion on adjusted...

Pear Therapeutics

BTIG starts Pear Therapeutics at buy; PT $12

BTIG initiated coverage of Pear Therapeutics (NASDAQ:PEAR) with a “buy” rating and $12 price target. The stock closed at $6.20 on Dec. 31.  Pear is a leader in prescription digital therapeutics (PDTs), with three...

Vincerx Logo

Cantor starts Vincerx Pharma at OW; PT $25

Cantor Fitzgerald initiated coverage of Vincerx Pharma (NASDAQ:VINC) with an “overweight” rating and $25 price target. The stock closed at $10.30 on Dec. 22. Vincerx is a clinical-stage oncology company that is on track...

BioCardia

HCW starts BioCardia at buy; PT $9

H.C Wainwright initiated coverage of BioCardia (NASDAQ:BCDA) with a “buy” rating and price target of $9. The stock closed at $1.71 on Dec. 17. BioCardia is a clinical-stage company focused on the development of cell...

ayala logo

Maxim starts Ayala at buy; PT $22

Maxim Group initiated coverage of Ayala Pharmaceuticals (NASDAQ:AYLA) with a “buy” rating and $22 price target. The stock closed at $9 on Dec. 17. Ayala is developing two gamma-secretase inhibitors – AL101 and...

89bio

HCW starts 89bio at buy; PT $46

H.C. Wainwright launched coverage of 89bio (NADAQ:ETNB) with a “buy” rating and price target of $46. The stock closed at $11.48 on Dec. 17. 89bio is a clinical-stage biopharmaceutical company focused on the development...

Vor Logo

HCW starts Vor Biopharma at buy; PT $26

H.C. Wainwright initiated coverage of Vor Biopharma (NASDAQ:VOR) with a “buy” rating and $26 price target. The stock closed at $12.13 on Dec. 16. Vor is a clinical-stage cell therapy company focused on developing...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.